Back HIV/AIDS HIV/AIDS Topics HIV Treatment

Cobicistat Booster Is a Safe and Effective Alternative to Ritonavir

The novel pharmacoenhancer cobicistat boosts blood levels of atazanavir (Reyataz) as well as ritonavir (Norvir) and is generally safe and well-tolerated over 48 weeks, according to final study results published in the July 1, 2013, Journal of Infectious Diseases.

alt

Read more:

FDA to Hold Public Meeting on Patient-Focused Drug Development and HIV Cure Research

On June 14, the U.S. Food and Drug Administration (FDA) will host a public meeting on patient-focused HIV drug development and cure-related research at its Maryland headquarters, the agency announced this month. Participants are requested to register by June 5.alt

Read more:

Very Early Antiretroviral Therapy Does Not Prevent Immune Activation

People who started antiretroviral therapy (ART) during acute HIV infection and experienced sustained viral suppression saw a substantial decrease in immune activation markers on their CD8 T-cells after 2 years of treatment, but often not to the level seen in HIV negative individuals, according to a report in the April 15, 2013, Journal of Acquired Immune Deficiency Syndromes.

alt

Read more:

UNAIDS: More than 7 Million Africans on HIV Treatment, Deaths Continue to Fall

The number of people in Africa receiving antiretroviral medications increased from less than 1 million in 2005 to an estimated 7.1 million in 2012, according to a new report from UNAIDS. The report also notes that AIDS-related deaths and new HIV infections have both fallen by about 30% over the past decade.  alt

 

Read more:

Updated Opportunistic Infection Guidelines Add Info on IRIS, Hepatitis, Drug Interactions

On May 7 the National Institutes of Health, Centers for Disease Control and Prevention, and HIV Medicine Association of the Infectious Diseases Society of Americaannounced the release of revised Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, updating the previous version from 2009.

alt

Read more:

Sangamo Reports Zinc Finger Gene Therapy Leads to Long-term CD4 Cell Gains, Shrinking HIV Reservoirs

An experimental gene therapy technique that modifies CD4 T-cells to protect them from viral entry produced lasting CD4 cell increases with a single infusion, as well as reduction in proviral DNA reservoirs and decreased viral load in 2 patients who underwent antiretroviral therapy (ART) interruption, according to data presented this week at the 16th Annual Meeting of the American Society of Gene and Cell Therapy in Salt Lake City.

alt

Read more:

Efavirenz More Effective than Nevirapine for Children with HIV

HIV positive African children and adolescents treated with efavirenz (Sustiva) were less likely to experience virological failure than those using nevirapine (Viramune), according to a large comparative study published in the May 1, 2013, Journal of the American Medical Association. Nevirapine, however, is less expensive and more widely available for children in low-income countries.

alt

Read more: